Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBITDA Margin (2020 - 2025)

Cytek Biosciences' EBITDA Margin history spans 6 years, with the latest figure at 68.64% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 8527.0% year-over-year to 68.64%; the TTM value through Dec 2025 reached 31.92%, down 2956.0%, while the annual FY2025 figure was 31.92%, 2956.0% down from the prior year.
  • EBITDA Margin reached 68.64% in Q4 2025 per CTKB's latest filing, down from 8.83% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 16.63% in Q4 2024 to a low of 68.64% in Q4 2025.
  • Average EBITDA Margin over 5 years is 7.14%, with a median of 4.47% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: surged 1548bps in 2024, then plummeted -8527bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 1.52% in 2021, then soared by 585bps to 7.35% in 2022, then soared by 36bps to 9.97% in 2023, then soared by 67bps to 16.63% in 2024, then crashed by -513bps to 68.64% in 2025.
  • Per Business Quant, the three most recent readings for CTKB's EBITDA Margin are 68.64% (Q4 2025), 8.83% (Q3 2025), and 10.99% (Q2 2025).